Brokers Offer Predictions for OS Therapies Q3 Earnings

Key Points

• Brookline Capital Markets raised its Q3 2026 EPS estimate for OS Therapies to a loss of $0.16 from a previous loss estimate of $0.19. The firm projects the company will reach profitability in FY2029, with estimated EPS of $0.16.
• Analyst sentiment is broadly positive, with three Buy ratings and one Hold rating, producing a “Moderate Buy” consensus and an average price target of $13.33.
• OS Therapies shares opened at $1.82, compared with a 12-month range of $1.15 to $2.35; the company most recently reported a quarterly loss of $0.20 per share.

OS Therapies Incorporated (NYSEAMERICAN:OSTX - Free Report) - Analysts at Brookline Capital Markets boosted their Q3 2026 earnings estimates for OS Therapies in a research report issued to clients and investors on Tuesday, September 8th. Brookline Capital Markets analyst K. Raja now expects that the company will earn ($0.16) per share for the quarter, up from their previous forecast of ($0.19). The consensus estimate for OS Therapies' current full-year earnings is ($0.77) per share. Brookline Capital Markets also issued estimates for OS Therapies' Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.22) EPS, FY2028 earnings at ($0.10) EPS, FY2029 earnings at $0.16 EPS and FY2030 earnings at $0.24 EPS.

Other equities analysts also recently issued research reports about the company. Roth Capital assumed coverage on OS Therapies in a report on Thursday, July 9th. They set a "buy" rating and a $7.00 price target on the stock. Lake Street Capital reduced their price objective on shares of OS Therapies from $14.00 to $13.00 and set a "buy" rating for the company in a research note on Tuesday, May 19th. Finally, Zacks Research raised shares of OS Therapies from a "strong sell" rating to a "hold" rating in a report on Thursday, June 4th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $13.33.

OS Therapies Stock Performance

Shares of OSTX stock opened at $1.82 on Friday. The stock's 50 day simple moving average is $1.62 and its 200 day simple moving average is $1.62. OS Therapies has a twelve month low of $1.15 and a twelve month high of $2.35. The company has a market capitalization of $83.96 million, a price-to-earnings ratio of -1.67 and a beta of -0.68.

OS Therapies (NYSEAMERICAN:OSTX - Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.20) earnings per share for the quarter.

Institutional Trading of OS Therapies

Several hedge funds have recently added to or reduced their stakes in OSTX. Millennium Management LLC acquired a new position in OS Therapies during the 3rd quarter valued at $183,000. Two Sigma Investments LP acquired a new stake in OS Therapies in the 3rd quarter worth $169,000. Geode Capital Management LLC increased its holdings in shares of OS Therapies by 31.1% during the 4th quarter. Geode Capital Management LLC now owns 246,038 shares of the company's stock worth $344,000 after purchasing an additional 58,350 shares during the period. Virtu Financial LLC increased its holdings in shares of OS Therapies by 252.0% during the 3rd quarter. Virtu Financial LLC now owns 75,801 shares of the company's stock worth $149,000 after purchasing an additional 54,269 shares during the period. Finally, XTX Topco Ltd acquired a new position in shares of OS Therapies during the second quarter valued at about $63,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.